NLRP3 and early-onset autosomal dominant Alzheimer disease: Nonsteroidal anti-inflammatory drugs (NSAIDs) have shown potential in delaying the onset of Alzheimer’s disease (AD) or reducing its risk, likely through their modulation of the NLRP3 inflammasome pathway (103).